Evidence map›Paper›PMID 42665404›Full record

ArticleIn vivo (Athens, Greece)

Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer.

Teruhisa Sakamoto, Kei Urakami, Kentaro Uehira, Jun Yoshida, Mikiya Kishino, Masaki Morimoto, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Teruhisa SakamotoDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan tesakamo@tottori-u.ac.jp.
Kei UrakamiDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Kentaro UehiraDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Jun YoshidaDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Mikiya KishinoDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Masaki MorimotoDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Yuki MurakamiDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Kozo MiyataniDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Yuji ShishidoDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Kyoichi KiharaDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Manabu YamamotoDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Tomoyuki MatsunagaDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.
Yoshiyuki FujiwaraDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe C-reactive protein-albumin-lymphocyte (CALLY) index is a novel prognostic biomarker that simultaneously evaluates three statuses: nutritional, immunological, and inflammatory. In this study, we aimed to clarify the prognostic significance of the CALLY index compared with that of the cachexia index (CXI), another comprehensive biomarker reflecting the three statuses, for patients with recurrent pancreatic cancer. PATIENTS AND

methodsThis retrospective study enrolled 129 patients diagnosed with recurrence following pancreatectomy for pancreatic cancer. The patients were divided into low CALLY (n=46) and high CALLY (n=83) index groups using a cut-off value of 3.25 for the CALLY index at the time of recurrence to analyze the association between the CALLY index and patient prognosis.

resultsThe post-recurrence overall survival (OS) rate and median duration of survival for the patients in this study were 6.1% and 398 days, respectively. The low CALLY group had a significantly worse 2-year post-recurrence OS than the high CALLY group (

conclusionAt the time of recurrence, patients with a low CALLY index have poor survival compared with those with a high CALLY index. Determining the CALLY index value at the time of recurrence may help to establish optimal treatment strategies to provide a meaningful quality of life for patients with recurrent pancreatic cancer.

Indexed as

Biomarkers, TumorC-Reactive ProteinLymphocytesNeoplasm Recurrence, LocalPancreatic NeoplasmsSerum AlbuminAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorC-Reactive ProteinSerum AlbuminCALLY indexpost-recurrence survivalrecurrent pancreatic cancer

Identifiers

PMID42665404
PMCPMC13531151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.